

MET One Step **Methamphetamine** Test Strip (Urine) **Package Insert**

MET-101 Cat: Format: Strip Z Version: Effective Date: 2020-07

For professional in vitro diagnostic use only.

INTENDED USE

The MET One Step Methamphetamine Test Strip (Urine) is a lateral flow chromatographic immunoassay for the detection of Methamphetamine in urine at a cut-off concentration of 1000 ng/mL. This test will detect other related compounds, please refer to the Analytical Specificity table in this package insert.

This assay provides only a qualitative, preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are

INTRODUCTION

Methamphetamine is an addictive stimulant drug that strongly activates certain systems in the brain. Methamphetamine are greater. Methamphetamine is made in illegal laboratories and has a high potential for abuse and dependence. The drug can be taken orally, injected, or inhaled. Acute higher doses lead to enhanced stimulation of the central nervous system and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to Methamphetamine include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, psychotic behavior, and eventually, depression and exhaustion.

The effects of Methamphetamine generally last 2-4hours and the drug has a half-life of 9-24 hours in the body. Methamphetamine is excreted in the urine primarily as amphetamine and oxidized and deaminated derivatives. However, 10-20% of Methamphetamine is excreted unchanged. Thus, the presence of the parent compound in the urine indicates Methamphetamine use. Methamphetamine use.

The MET One Step Methamphetamine Test Strip (Urine) yields a positive result when the concentration of Methamphetamine exceeds 1000ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

PRINCIPLE

The MET One Step Methamphetamine Test Strip (Urine) is an immunoassay based on the principle of competitive binding. Drugs that may be present in the urine specimen compete against the drug conjugate for binding sites on the antibody.

During testing, a urine specimen migrates upward by capillary action. Methamphetamine, if present in the urine specimen below the cut-off level, will not saturate the binding sites of the antibody in the test. The antibody coated particles will then be captured by immobilized Methamphetamine-protein conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the Methamphetamine level exceeds the cut-off level, because it will saturate all the binding sites of anti-Methamphetamine antibodies.

A drug-positive urine specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative urine specimen or a specimen containing a drug concentration less than the cutoff will generate a line in the test line region. To serve as a procedural control, a colored line will always appear at the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.

REAGENTS

The test contains drug-bovine protein antigen conjugate on the membrane and the conjugate pad of each test contains monoclonal antidrug antibody.

KIT COMPONENTS

Individually packed Test Strips

Each Strip contains a strip with colored conjugates and reactive reagents prespreaded at the corresponding regions.

Package insert

For operation instruction.

MATERIALS REQUIRED BUT NOT PROVIDED

Timer

Specimen collection container For specimens collection use. For timing use.

PRECAUTIONS

- For professional in vitro diagnostic use only.
- Do not use after expiration date indicated on the package. Do not use the test if its foil pouch is damaged. Do not reuse tests.
- This kit contains products of animal origin. Certified knowledge of the origin and/or sanitary state of the animals does not totally guarantee the absence of transmissible pathogenic agents. It is therefore. recommended that these products be treated as potentially infectious, and handled observing the usual safety precautions (do not ingest or
- · Avoid cross-contamination of specimens by using a new specimen collection container for each specimen obtained.
- Read the entire procedure carefully prior to performing any tests.
- Do not eat, drink or smoke in the area where the specimens and kits are handled. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the procedure and follow the standard procedures for proper disposal of specimens. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
- Humidity and temperature can adversely affect results.
- The used testing materials should be discarded in accordance with local, state and/or federal regulations.

STORAGE AND STABILITY

- The kit should be stored at 2-30°C until the expiry date printed on the sealed pouch.
- The test must remain in the sealed pouch until use.
- Do not freeze.
- · Cares should be taken to protect components in this kit from contamination. Do not use if there is evidence of microbial contamination or precipitation. Biological contamination of dispensing equipment, containers or reagents can lead to false results.

SPECIMEN COLLECTION AND STORAGE

- The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible particles should be centrifuged, filtered, or allowed to settle to obtain clear specimen for testing.
- Collected urine specimens must be put in clear and dry containers.
- Perform the testing immediately after the specimen collection. Do not leave the specimens at room temperature for prolonged periods.

- Specimens may be stored at 2-8°C for up to 48 hours. For long term storage, specimens should be kept below -20°C.
- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Avoid repeated freezing and thawing of specimens.
- Pack the specimens in compliance with applicable regulations for transportation of etiological agents, in case they need to be shipped.

PROCEDURE

Bring tests, specimens and/or controls to room temperature (15-30°C) before use.

- 1. Bring the pouch to room temperature before opening it. Remove the test Strip from the sealed pouch and use it as soon as possible.
- 2. Prepare a container with appropriate amount of urine. **Dip the test** strip vertically in the urine specimen for at least 8-10 seconds. then start the timer, and Place the test Strip on a clean and level surface. Avoid let the urine exceed the max line.
- 3. Wait for the colored line(s) to appear. Read results at 5 minutes. Do not interpret the result after 10 minutes.

INTERPRETATION OF RESULTS

POSITIVE RESULT:



Only one colored band appears in the control region (C). No apparent colored band appears in the test region (T).

NEGATIVE RESULT:



Two colored bands appear on the membrane. One band appears in the control region (C) and another band appears in the test region

INVALID RESULT:



Control band fails to appear. Results from any test which has not produced a control band at the specified reading time must be discarded. Please review the procedure and repeat with a new test. If the problem persists, discontinue using the kit immediately and contact your local distributor.

NOTE:

- 1. The intensity of the color in test region (T) may vary depending on the concentration of aimed substances present in the specimen. Therefore, any shade of color in the test region should be considered negative. Besides, the concentration level can not be determined by this qualitative test.
- 2. Insufficient specimen volume, incorrect operation procedure, or performing expired tests are the most likely reasons for control band failure.

OUALITY CONTROL

- Internal procedural controls are included in the test. A colored band appearing in the control region (C) is considered an internal positive procedural control. It confirms sufficient specimen volume and correct procedural technique.
- External controls are not supplied with this kit. It is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS OF THE TEST

- 1. The MET One Step Methamphetamine Test Strip (Urine) provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. 1,2
- 2. It is possible that technical or procedural errors, as well as other interfering substances in the urine specimen may cause erroneous results.

- 3. Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- 4. A positive result indicates presence of the drug or its metabolites but does not indicate level of intoxication, administration route or concentration in urine.
- 5. A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- 6. Test does not distinguish between drugs of abuse and certain medications.

PERFORMANCE CHARACTERISTICS

A. Accuracy

127clinical urine specimens were analyzed by GC-MS and by the MET One Step Methamphetamine Test Strip (Urine). Each test was performed by three operators. Samples were divided by concentration into five categories: negative, less than half the cutoff, near cutoff negative, near cutoff positive, and high positive. Results were as follows:

Me	ethod	GC/MS					
The MET One Step Methamphetamin e Test Strip		Ne g.	Neg. (< - 50% cutof f)	Near cutoff neg. (-50% cutoff to cutoff)	Near cutoff pos. (cutoff to +50% cutoff)	Pos. (> +50 % cuto ff)	% agreeme nt with GC/MS
MET	Positive	0	0	0	11	31	95.45%
1000	Negative	55	17	11	2	0	100%

B. Precision

A study was conducted at three physician offices for Methamphetamine (1000 ng/mL)by professional operators using three different lots of product to demonstrate the within run, between run and between operator precision.An identical panel of coded specimens, containing drugs at the concentration of \pm 50% and \pm 25% cut-off level, was labeled as a blind and tested at each site. The results are given below:

Drug Conc.	n	Site A		Sit	е В	Site C	
Di ug Colic.	per site	-	+	-	+	-	+
Negative	10	10	0	10	0	10	0
-50% Cut-off	10	10	0	10	0	10	0
-25% Cut-off	10	10	0	10	0	10	0
+25% Cut-off	10	1	9	0	10	1	9
+50% Cut-off	10	0	10	0	10	0	10

C. Effect of Urinary Specific Gravity

Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.000-1.037) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The MET One Step Methamphetamine Test Strip (Urine) was tested in duplicate using fifteen drug free urine and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results.

D. Effect of Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pH adjusted urine was tested with the MET One Step Methamphetamine Test Strip (Urine). The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

E. Cross-Reactivity

The following tables list the concentrations of compounds (ng/mL) above which the MET One Step Methamphetamine Test Strip (Urine) identified positive results at 5 minutes.

Methamphetamine related Compound	Concentration (ng/mL)		
l -Methamphetamine	8000		
d-Amphetamine	100000		
l-Amphetamine	100000		
3,4- Methylenedioxymethamphetamine(MDMA)	2500		
d,l- Methylenedioxy ethylamphetamine(MDEA)	20000		

F. Non Cross-Reacting Compounds

The following compounds yielded negative results up to a concentration of $100 \, \mu g/mL$:

4-Acetamidophenol	Gatifloxacin	Penfluridol	
Acetaminophen	Gemfibrozil	Penicillin G potassium salt	
Acetylsalicylic Acid Albumin Amoxicillin Ampicillin Ampicillin trihydrate Aspartame Atropine Baclofen Benzoic Acid Berberine Chloride	Gentisic Acid Gliclazide Glipizide Glyburide Guaiacol Guaifenesin Hemoglobin Hydralazine HCl Hydrochlorothiazide	Penicillin G sodium salt Perphenazine Phenacetin Phenelzine Sulfate Phenothiazine 2-Phenylethylamine Pioglitazone Piracetam Pravastatin sodium	
Hydrate	Hydrocortisone	Prednisone	
Bilirubin Caffeine	Ibuprofen Isoprenaline	Procaine Promethazine hydrochlorine	
Cephalexin Cephradine Chloral hydrate Chloramphenicol	Ketoconazole Ketoprofen Lamotrigine L-Ascorbic acid	6-Propyl-2-thiouracil Pyridoxine Pyrilamine Maleate Pyrogallic	
Chlorpheniramine Maleate	Levofloxacin	Quetiapine Fumarate	
Chlorpromazine Cholesterol Ciprofloxacin hydrate Clarithromycin Clonidine solution Creatinine D(-)-Norgestrel d,l-Propranolol Deoxycorticosterone	Lidocaine Lidocaine Monohydrate Lisinopril Dihydrate Lithium carbonate Loperamide Loratadine L-Thyroxine sodium Maprotiline Meprobamate	Quinine Quinolinic acid R,R(-)-Pseudoephedrine Ranitidine base Ranitidine Riboflavin Rifampicin Risperidone Salicylic acid	
Cholesterol Ciprofloxacin hydrate Clarithromycin Clonidine solution Creatinine D(-)-Norgestrel d,l-Propranolol	Lidocaine Monohydrate Lisinopril Dihydrate Lithium carbonate Loperamide Loratadine L-Thyroxine sodium Maprotiline	Quinolinic acid R,R(-)-Pseudoephedrine Ranitidine base Ranitidine Riboflavin Rifampicin Risperidone	
Cholesterol Ciprofloxacin hydrate Clarithromycin Clonidine solution Creatinine D(-)-Norgestrel d,l-Propranolol Deoxycorticosterone Dextromethorphan	Lidocaine Monohydrate Lisinopril Dihydrate Lithium carbonate Loperamide Loratadine L-Thyroxine sodium Maprotiline Meprobamate	Quinolinic acid R,R(-)-Pseudoephedrine Ranitidine base Ranitidine Riboflavin Rifampicin Risperidone Salicylic acid Sertraline HCl Simvastatin	
Cholesterol Ciprofloxacin hydrate Clarithromycin Clonidine solution Creatinine D(-)-Norgestrel d,l-Propranolol Deoxycorticosterone Dextromethorphan solution Diciofenac Diflunisal	Lidocaine Monohydrate Lisinopril Dihydrate Lithium carbonate Loperamide Loratadine L-Thyroxine sodium Maprotiline Meprobamate Minocycline Mosapride Citrate Nalidixic acid	Quinolinic acid R,R(-)-Pseudoephedrine Ranitidine base Ranitidine Riboflavin Rifampicin Risperidone Salicylic acid Sertraline HCl Simvastatin Sodium 2- Propylvalerate	
Cholesterol Ciprofloxacin hydrate Clarithromycin Clonidine solution Creatinine D(-)-Norgestrel d,l-Propranolol Deoxycorticosterone Dextromethorphan solution Diciofenac Diflunisal Digoxin 4-Dimethyl-	Lidocaine Monohydrate Lisinopril Dihydrate Lithium carbonate Loperamide Loratadine L-Thyroxine sodium Maprotiline Meprobamate Minocycline Mosapride Citrate	Quinolinic acid R,R(-)-Pseudoephedrine Ranitidine base Ranitidine Riboflavin Rifampicin Risperidone Salicylic acid Sertraline HCl Simvastatin Sodium 2-	
Cholesterol Ciprofloxacin hydrate Clarithromycin Clonidine solution Creatinine D(-)-Norgestrel d,l-Propranolol Deoxycorticosterone Dextromethorphan solution Diciofenac Diflunisal Digoxin 4-Dimethyl- aminoantipyrine Diphenhydramine 5,5-Diphenylhydantoin D-Lactose monohydrate	Lidocaine Monohydrate Lisinopril Dihydrate Lithium carbonate Loperamide Loratadine L-Thyroxine sodium Maprotiline Meprobamate Minocycline Mosapride Citrate Nalidixic acid Naloxone HCl	Quinolinic acid R,R(-)-Pseudoephedrine Ranitidine base Ranitidine Riboflavin Rifampicin Risperidone Salicylic acid Sertraline HCl Simvastatin Sodium 2- Propylvalerate Sulfamethazine	
Cholesterol Ciprofloxacin hydrate Clarithromycin Clonidine solution Creatinine D(-)-Norgestrel d,l-Propranolol Deoxycorticosterone Dextromethorphan solution Diciofenac Diflunisal Digoxin 4-Dimethyl- aminoantipyrine Diphenhydramine 5,5-Diphenylhydantoin	Lidocaine Monohydrate Lisinopril Dihydrate Lithium carbonate Loperamide Loratadine L-Thyroxine sodium Maprotiline Meprobamate Minocycline Mosapride Citrate Nalidixic acid Naloxone HCl Naltrexone HCl Naproxen Nicotinamide	Quinolinic acid R,R(-)-Pseudoephedrine Ranitidine base Ranitidine Riboflavin Rifampicin Risperidone Salicylic acid Sertraline HCl Simvastatin Sodium 2- Propylvalerate Sulfamethazine Sulindac Tetracycline Tetrahydrozoline	

Droperidol Enalapril Maleate	Norethisterone Acetate Norfloxacin Nicotinic	Tolbutamide Topiramate
Erythromycin	Noscapine	2,4,7-Triamino-6- Phenylpteridine
Estradiol	(±)-Octopamine	Trimethoprim
Estrone Ethyl 4-aminobenzoate Fluoxetine	Ofloxacin Olanzapine Oxalic acid, anhydrous	Tryptamine Tyramine Uric acid
Fotemustine	Oxolinic acid	(±)-Verapamil
Furosemide Gabapentin	Paliperidone Pantoprazole sodium	Vitamin B1 Zomepirac

LITERATURE REFERENCES

- 1. Baselt RC. <u>Disposition of Toxic Drugs and Chemicals in Man.</u> 2nd Ed. Biomedical Publ., Davis, CA. 1982; 488
- Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986

Index of Symbols

[]i	Consult Instruction for use	Σ	Tests per kit	®	Do not use if package is damaged
IVD	For in vitro diagnostic use only	\square	Use by date	(2)	Do not reuse
2°C 30°C	Store between 2-30°C	LOT	Lot Number	REF	Catalogue number
淡	Keep away from sunlight	*	Keep dry	•••	Manufacturer
Ţ	Caution	سا	Date of manufacture	EC REP	Authorized Representative



 $Hangzhou\ Sejoy\ Electronics\&\ Instruments\ Co., Ltd.$

Area C, Building 2, No.365, Wuzhou Road, Yuhang Economic Development Zone, Hangzhou City 311100 Zhejiang China Website: www.sejoy.com



Shanghai International Holding Corp. GmbH (Europe) Eiffestrasse 80, 20537 Hamburg, Germany

